Radiotherapy · Theranostics · Liver/Hepatic Cancer · Patient Safety · Radiobiology
Hybrid Radionuclide Therapy Enhances Treatment Efficacy in NET Liver Metastases
November 18, 2026 · News Release
Source: snmmi.org

Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) enhances the treatment of liver-dominant metastatic neuroendocrine tumors (NETs), delivering significantly higher radiation directly to liver metastases while maintaining systemic coverage. This hybrid strategy has shown promising results in a recent study published in The Journal of Nuclear Medicine.
As gastroenteropancreatic NETs increasingly present with liver metastases, effective treatment options are crucial. Standard therapies, including systemic agents and chemotherapy, typically provide limited control, with a median progression-free survival of around 1.5 years. Researchers explored a personalized approach, administering 177Lu-DOTATATE through hepatic arteries followed by intravenous therapy to determine feasibility, safety, and effectiveness.
The prospective pilot study involved 10 patients with progressive, liver-dominant metastatic gastroenteropancreatic NETs who underwent four cycles of treatment: two initial intraarterial followed by two intravenous cycles, each given every two months. Safety assessments indicated successful intraarterial administration in all patients, with no contamination events reported. Dosimetric analysis confirmed that intraarterial delivery resulted in over three times higher radiation exposure to liver metastases compared to the intravenous method.
Notably, 68Ga-DOTATATE PET imaging showed an 86% increase in median liver lesion uptake when using the intraarterial route. Efficacy results indicated a partial response rate of 67% at three months, improving to 87% at the six-month follow-up.
Dr. Lisa Bodei from Memorial Sloan Kettering Cancer Center emphasized that this study highlights a clinically integrated hybrid strategy that combines delivery, dosimetry, safety, and response measures in a single prospective cohort. This advancement may offer patients improved tumor control and a more individualized treatment regimen.
The research, titled "Optimizing the Therapeutic Index: Sequential Intraarterial–Intravenous PRRT with Personalized Volumetric-Adjusted Dosing," includes contributions from various professionals within the Molecular Imaging and Therapy and Department of Radiology at Memorial Sloan Kettering Cancer Center, alongside other affiliated departments.
Further details and insights can be found on the Journal of Nuclear Medicine's website.

